{
    "clinical_study": {
        "@rank": "50087", 
        "arm_group": [
            {
                "arm_group_label": "sulfasalazine", 
                "arm_group_type": "Experimental", 
                "description": "1 g oral twice daily for 2 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "oral placebo pill twice daily for two weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that sulfasalazine, an FDA-approved medication for rheumatoid\n      arthritis and ulcerative colitis, may be beneficial in neuropathic pain conditions. In this\n      study, the investigators will evaluate whether sulfasalazine improves pain due to diabetic\n      peripheral neuropathy."
        }, 
        "brief_title": "Study of Sulfasalazine in Treating Painful Diabetic Neuropathy", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Painful Diabetic Neuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Neuropathies", 
                "Pain", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HgbA1c between 6.5 and 11\n\n          -  Michigan Neuropathy Screening Instrument score of 3 or greater\n\n          -  no obvious alternative explanation for neuropathy\n\n          -  average baseline pain > 4/10\n\n        Exclusion Criteria:\n\n          -  other severe pain\n\n          -  anticipated difficulty weaning off medications\n\n          -  past or current psychiatric disorder as determined by Mini International\n             Neuropsychiatric Interview\n\n          -  medical contraindication to sulfasalazine\n\n          -  not proficient in English (due to heavy use of questionaires)\n\n          -  pregnant or breast feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667029", 
            "org_study_id": "2012-p-001443"
        }, 
        "intervention": [
            {
                "arm_group_label": "sulfasalazine", 
                "intervention_name": "Sulfasalazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sulfasalazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Jared Beaumont, BA", 
                "phone": "617-726-5186"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Diabetic Neuropathy", 
        "overall_contact": {
            "email": "jbeaumont@partners.org", 
            "last_name": "Jared Beaumont, BA", 
            "phone": "617-726-5186"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Brian J Wainger, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Average pain score will be the average of daily pain scores (0-10) recorded by the subject during the second week of the two week treatment period.", 
            "measure": "pain score", 
            "safety_issue": "No", 
            "time_frame": "second week of two week treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667029"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Brian Wainger", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be assessed using the Brief Pain Inventory Interference and Euroquality of Life metrics", 
                "measure": "Physical Functioning Score", 
                "safety_issue": "No", 
                "time_frame": "Assessed at end of two week treatment period"
            }, 
            {
                "description": "Will be assessed by the Beck Depression Inventory metric", 
                "measure": "Emotional Functioning", 
                "safety_issue": "No", 
                "time_frame": "Assessed at end of two week treatment period"
            }, 
            {
                "description": "Will be assessed using the Patient Global Impression of Change metric", 
                "measure": "Overall Improvement", 
                "safety_issue": "No", 
                "time_frame": "Will be assessed at end of two week treatment period"
            }, 
            {
                "description": "Assessed using description as \"none, mild, moderate, or severe\"", 
                "measure": "Categorical rating of pain intensity", 
                "safety_issue": "No", 
                "time_frame": "Assessed at end of two week treatment period"
            }, 
            {
                "description": "Number of times breakthrough pain medication was taken", 
                "measure": "Breakthrough Treatment", 
                "safety_issue": "No", 
                "time_frame": "Assessed during two week treatment period"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}